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ABSTRACT
Introduction: A range of combination chemotherapy regimens are currently used in clinical practice.
However, international antiemetic guidelines often only categorize the emetogenic potential of single
agents rather than the emetogenicity of combination chemotherapy regimens. To manage the nausea
and vomiting induced by antineoplastic combinations, guidelines suggest antiemetics that are appropriate
for the component drug with the highest emetogenic potential. Furthermore, antiemetic guidelines gen-
erally do not consider the influence of other factors, including individual patient characteristics, on the
emetic effects of cancer treatments. Similarly, the emetogenic potential of radiotherapy is stratified only
according to the site of radiation, while other factors contributing to emetic risk are overlooked.
Areas covered: An Expert Panel was convened to examine unresolved issues and summarize the
current clinical research on managing nausea and vomiting associated with combination chemotherapy
and radiotherapy.
Expert opinion: The panel identified the incidence of nausea and vomiting induced by multi-drug
combination therapies currently used to treat cancer at different anatomic sites and by radiotherapy in
the presence of other risk factors. Based on these data and the clinical experience of panel members,
several suggestions are made for a practical approach to prevent or manage nausea and vomiting due
to chemotherapy regimens and radiation therapy.
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1. Introduction
Nausea and vomiting are among the most frequent toxicities
associated with antineoplastic agents and radiation treatments
used for oncological patients, with an estimated incidence rate of
nearly 50% [1–3]. These burdensome adverse effects are highly
distressing and debilitating for patients, profoundly affecting
their quality of life and seriously compromising their compliance
with anticancer therapy, with detrimental consequences [4,5].
Not only are nausea and vomiting the strongest concerns
for patients and the most feared side effects of antitumoral
treatments, but their occurrence also markedly impairs their
own and their family’s daily activities [1,5]. Also, health-care
providers tend to underestimate the incidence of these symp-
toms, particularly delayed symptoms that do not develop
immediately following the administration of therapy [6].
Nausea and vomiting related to antitumoral therapies are so
important and characteristic that they are recognized as specific
and well-defined conditions known as CINV (chemotherapy-
induced nausea and vomiting) and RINV (radiotherapy-induced
nausea and vomiting) for which there are dedicated guidelines
by the Multinational Association of Supportive Care in Cancer
and the European Society for Medical Oncology (MASCC/ESMO),
the American Society of Clinical Oncology (ASCO) and the
National Comprehensive Cancer Network (NCCN) [7–12].
The main international antiemetic guidelines classify the
available single chemotherapeutic agents for anticancer treat-
ment into four groups according to their ‘level of emetogeni-
city’, that is, the expected frequency of emesis induced in the
absence of effective antiemetic prophylaxis [7,13].
Based on solid scientific evidence, the antiemetic guidelines
recommend a specific antiemetic approach for each emetogenic
level, which limits their applicability because the most common
and effective anticancer treatments are combinations of different
antineoplastic agents, not the administration of single drugs.
With the exception of the doxorubicin and cyclophosphamide
(AC) regimen for breast cancer, none of the guidelines has
established emetic-risk classes for combination regimens, gen-
erally stating that the emetogenic potential of the combination
CONTACT Paolo Bossi paolo.bossi@unibs.it Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health
University of Brescia, ASST-Spedali Civili, Piazza del Mercato 15, Brescia 25121, Italy
EXPERT OPINION ON DRUG SAFETY
2020, VOL. 19, NO. 2, 187–204
https://doi.org/10.1080/14740338.2020.1724955
© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/),
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
would automatically correspond to the potential of the compo-
nent drug with the highest emetic risk.
However, as learned through the results of clinical trials and
daily clinical practice, the emetogenic potentials of the differ-
ent agents included in a chemotherapy regimen may be
additive (in the case of drugs with a moderate or high emeto-
genic potential), so that the nausea and vomiting induced by
an antitumor drug varies according to its possible combina-
tion with other anticancer agents [14].
Moreover, the incidence and severity of CINV (and radiother-
apy or chemoradiation as well) is influenced by a wide range of
factors, including dosage, duration, schedule, and route of
administration of the agents, disease characteristics, and indivi-
dual patient characteristics, such as age, sex, previous experience
of chemotherapy or emesis during pregnancy, motion sickness,
history of alcohol use, etc. [9,15]. These important variables are
explicitly overlooked by the international antiemetic guidelines,
possibly because of a paucity of robust evidence [8,9,16]. As a
consequence, the emetic risk classificationmade by international
guidelines can be considered quite arbitrary.
RINV is a common side effect of radiation therapy (RT) that
negatively impacts patient quality of life [17]. Importantly, this
condition requires expensive supportive care and, in severe
cases, can result in treatment delays with a negative effect on
tumor control [18].
Both radiotherapy-related and patient-related risk factors
contribute to the incidence and severity of RINV [18]. Such factors
include the anatomic site of radiation, the volume of the irra-
diated organs, the radiation dose, and the fractionation schedule
(radiotherapy-related factors), along with age, gender, and con-
current or recent chemotherapy (patient-related factors) [18–20].
The IGARR (Italian Group for Antiemetic Research in
Radiotherapy) studies identified other relevant risk factors for
RINV: concomitant radiochemotherapy, previous experience of
vomiting caused by chemotherapy, site of irradiation (upper
abdomen), and field size (>400 cm2) seem to be significantly
correlated with a higher incidence of RINV [19,20].
However, current antiemetic guidelines use only the site of
irradiation to categorize the emetogenic potential of RT into four
risk categories (high, moderate, low, and minimal) [8,9,16]. The
same guidelines state that other known risk factors for the
occurrence of RINV, such as radiation dose, fractionation, techni-
que, field size, and concomitant chemotherapy, have not been
considered in the stratification of the emetic risk levels of RT,
recognizing only previous chemotherapy as a significant patient-
related risk factor [8,16,17].
An Italian Expert Panel, involving specialists from a range of
fields, was convened to discuss these unresolved issues. They
collected data in a non-systematic way from randomized and
controlled clinical trials in order to identify the incidence of
CINV and RINV, with a particular attention to patient- and
disease-related risk factors. The aim also was to highlight any
unmet needs in the prevention and control of CINV and RINV,
including disease- and patient-specific personalization of CINV
risk, the importance of considering the emetogenic risk of
combination chemotherapy, possible drug interactions, and
the use of different routes of antiemetic drug administration.
It should be noted that, while the authors have structured this
manuscript by different cancer types, research into antiemetic
therapy is often based on the emetogenicity of different anti-
neoplastic regimens, rather than on specific diseases.
Based on the experience gained in clinical practice and
reported in the most recent scientific literature available, the
authors provide suggestions for the management of CINV and
RINV. They describe the antiemetic approaches that they com-
monly offer to their own patients, under conditions not covered
by the guidelines and/or to address limitations of these guidelines.
2. CINV in different pathological conditions
Table 1 briefly summarizes the epidemiology and key antitumor
treatment strategies for the conditions covered in this section.
2.1. CINV in head and neck cancer patients
Cisplatin is commonly employed in patients with locally
advanced disease (Table 1). Since cisplatin is classified as a highly
emetogenic chemotherapy, one may expect a high risk of CINV
in this disease, which is increased by the concurrent administra-
tion of RT. However, the emetic risk in this patient population is
influenced by two factors which should be considered when
identifying the individual predisposition to this side effect. On
one hand, alcohol addiction, which is one of the main risk factors
for head and neck cancers (HNC), is actually associated with a
diminished risk of emesis. On the other hand, the role of human
papillomavirus (HPV) as a causal factor is increasing and patients
with HPV infection are much less prone to heavy alcohol intake,
so this cancer population could have a higher risk of CINV [61].
The pattern of emetic symptoms has been depicted by Chan and
colleagues in an interesting study evaluating different cisplatin
schedules (Table 2) [62]. The incidence of vomiting was shown to
be similar with single-day and multiple-day regimens, while the
incidence of nausea was higher in patients receiving a single-day
regimen than in those receiving a multiple-day regimen.
2.1.1. Unmet needs in the control of nausea and vomiting
in this patient population
In HNC, the disease and its treatment can increase the overall risk
of nausea and vomiting, making CINV and RINV particularly
Article highlights
● The international antiemetic guidelines only partially consider the
emetogenic risk of combination chemotherapy regimens.
● Guidelines for treatment of RINV have not yet been updated to
consider the use of modern technologies, taking into account differ-
ent risks and the corresponding preventive approaches.
● The prevention of nausea and vomiting in the continuous adminis-
tration of oral chemotherapy or targeted agents is another unmet
need.
● Antiemetic therapy should be targeted to individual patients’ needs,
based on the emetogenic potential of their antineoplastic regimen, as
well as patient- and disease-specific risk factors.
● New approaches in prevention and treatment of CINV and RINV may
derive from new drugs, new combinations or the use of different
formulations.
This box summarizes key points contained in the article.
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Table 1. Epidemiology and common antitumor treatment strategies for some of the cancers discussed.
Cancer site Epidemiology Antitumor treatment
Head and neck ● 6th most common cancer subsite worldwide, with a gradual change
in epidemiology in the last 10 years
● The incidence of HPV-related oropharyngeal cancer is expected to
continue increasing in the next 20 years [61]
● Curative or postoperative strategy in locally advanced disease: RT +
systemic therapy (mainly cisplatin)
● Recurrent/metastatic: Platinum- and cetuximab-based treatment
first line
Lung SCLC:
● 15–20% of new cases of lung cancer worldwide [21]
● Median survival: 16–24 months (limited-stage disease), 6–12 months
(extensive-stage) [22,23]
● Most commonly prescribed first line: cisplatin + etoposide
● NSCLC with EGFR mutations: EGFR inhibitors
Breast ● Most common cancer in women worldwide
● Most patients diagnosed at early stage, but 7–10% diagnosed with
metastatic breast cancer at initial presentation and as many as 70%
of node-positive patients relapse [24,25]
● Numerous chemotherapeutic agents commonly used
● No established standard regimen in the metastatic setting
Gastric ● 4th most commonly diagnosed cancer worldwide [26]
● 2nd most common cause of cancer-related deaths worldwide [26]
● 5-year survival 19–31%; median OS <1 year [27–29]
● Most widely used: fluoropyrimidine-based and platinum-based
combination ± a 3rd drug (usually docetaxel or epirubicin) [30]
● Capecitibine (a fluoropyrimidines) was non-inferior to fluorouracil
(for PFS, OS) in clinical trials [31,32]
Pancreatic ● 13th most common cancer worldwide [33]
● 4th leading cause of cancer death in the Western world [33]
● 5-year survival, 9.7%; median OS, 4.4 months [33]
● Advanced disease: gemcitabine became the reference treatment
after demonstrating improved OS compared with 5-fluorouracil
[34]
● Clinical activity has also been demonstrated with regimens incor-
porating irinotecan and oxaliplatin + 5-fluorouracil
● FOLFOXIRI demonstrated longer PFS and ORR than gemcitabine [35]
● Nanoparticle albumin bound-paclitaxel in combination with gemci-
tabine showed an improvement of PFS and response rate vs gem-
citabine [93]
Biliary tract ● Uncommon in developed countries ● No accepted standard palliative regimen, due to insufficient
robustness of studies [36]
● Fluoropyrimidines, platinum agents, and gemcitabine have shown
activity [36]
Colorectal ● 2nd leading cause of cancer-related death worldwide [37]
● Accounts for ≈10% of all diagnosed cancer cases and ≈9% of all
cancer-related deaths [37]
● Backbone of first-line chemotherapy: a fluoropyrimidine +
irinotecan or oxaliplatin; biologicals (targeted therapy) are often
added [38]
Soft-tissue
sarcoma
● Incidence 1.8–5 cases/100,000 population/year; account for 1% of
neoplasms in adults [39,40]
● For both adjuvant therapy and metastatic disease, chemotherapy is
based on anthracyclines, dacarbazine, ifosfamide, and etoposide
● Chemotherapy treatment schedules, including paclitaxel, gemcita-
bine, trabectedin, pazopanib, and olaratumab + doxorubicin, have
been recently introduced [41]
Melanoma ● In the US: 5th most common cancer in men and 6th in women; in
Italy: 2nd and 3rd most common cancer in men <50 years and
women <50 years old, respectively [42]
● Incidence has risen dramatically in recent years; however, mortality
rate has not changed markedly. In Italy, accounts for 1.0% of all
cancer-related deaths [43]
● Adjuvant therapy is historically based on interferon [110]
● New immunotherapeutic options have recently been approved (e.g.
ipilimumab, pembrolizumab, nivolumab) [44,45]
● Numerous targeted treatments have also been developed [46]
Myelodysplastic
syndrome
(MDS)
● Incidence 3–12 cases/100,000 population/year, increasing with age
[47,48]
● Secondary disease (for which it is possible to identify previous
hemopathy or exposure to myelotoxic substances) has worse prog-
nosis and greater treatment resistance than primary disease
● Low/intermediate-1-risk: based on high-dose erythropoietin and/or
transfusion and/or iron chelation
● MDS with deletion of the long arm of chromosome 5, and resistant
to first-line treatment with erythropoietin: immunomodulatory
therapy (e.g. lenalidomide)
● Intermediate-2- or high risk: supportive care + demethylating agents
● Bone marrow transplantation is reserved for young patients without
comorbidities (sometimes after pre-treatment with demethylating
agents)
Acute myeloid
leukemia
(AML)
● Most common leukemia in adults
● Incidence: 2–3/100,000 young adults; 13–15/100,000 people in their
60s or 70s [49]
● 5-year survival in patients aged >65 years is <5% [49]
● Conventional treatment includes two phases: induction and
consolidation
● Induction: standard in young, medical fit patients = anthracycline
(usually daunorubicin) + cytarabine + etoposide
● Consolidation (once complete remission achieved): intermediate/
high dose cytarabine + daunorubicin, or demethylating agents for
patients without hyperleukocytosis
● In frail patients, supportive therapy and hydroxyurea are indicated
for the control of leukocytosis [50–52]
● Demethylating agents can control disease without necessarily
achieving complete remission, and therefore provide an important
therapeutic option for patients whose options would otherwise
consist only of supportive therapy alone [53]
(Continued )
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challenging tomanage. Dysgeusia, concomitant infections of the
oral cavity, mucositis, sticky saliva, dysphagia, use of a feeding
tube, and concurrent use of opioids to alleviate mucositis pain
are all linked to an increased risk of emesis in HNC patients.
Overall, we are far from being able to completely control
CINV and RINV in HNC patients.
2.2. CINV in lung cancer patients
Table 3 summarizes reported incidence rates of CINV asso-
ciated with chemotherapy regimens used for small-cell lung
cancer (SCLC) and non-small cell lung cancer (NSCLC) [63–72].
In a randomized trial conducted in elderly patients with
SCLC, as would be expected, the split-dose cisplatin plus
etoposide course showed a significantly higher rate of nau-
sea/vomiting toxicity compared with an oxaliplatin plus eto-
poside regimen: 97.2% vs 65.7%; P = 0.001 (Table 3) [68].
Although carboplatin is considered to be moderately eme-
togenic, in one trial a carboplatin plus etoposide regimen gave
a very low incidence of grade 3–4 nausea and vomiting in
patients with SCLC (0.2% and 0.7% respectively; Table 3) [69].
In the Hoosier Oncology Group study in patients with SCLC,
the combination of split-dose cisplatin + ifosfamide + etopo-
side was associated with grade 3–4 nausea/vomiting toxicity
in 13.0% of patients (grade 4 = 4.0%), which was higher than
8% rate in patients receiving a regimen without ifosfamide
(grade 4 = 0.0%) (Table 3) [66].
Etoposide administered intravenously for 5 days or given
per os for 21 days to patients with SCLC gives a low incidence
of nausea/vomiting [73].
The epidermal growth factor receptor (EGFR) inhibitors (e.g.
afatinib, erlotinib, gefitinib), used in patients with NSCLC and
EGFR mutations, are characterized by a low rate of vomiting
toxicity; osimertinib, which is selective for both EGFR-tyrosine
kinase inhibitor sensitizing and T790M resistant mutations,
rarely causes grade 3 nausea/vomiting (1.0%) [74].
In patients with metastatic NSCLC, the next-generation anaplas-
tic lymphoma kinase inhibitors have demonstrated incidences of
grade 3–4 nausea and vomiting of 1.1% (alectinib), 10.9% (ceritinib),
and 1.4% (brigatinib), but a not negligible rate of all-grade CINV [75].
2.2.1. Unmet needs in the control of nausea and vomiting
in this patient population
Nausea and vomiting are frequent adverse effects of many lung
cancer treatments, including chemotherapy regimens and some
targeted therapies, although the emetogenic risk differs between
agents. A comprehensive intervention is needed to effectively
manage and relieve these symptoms which further impact the
quality of life of lung cancer patients already very debilitated by
their pathology and cancer treatments. In particular, attention
should be given to CINV management in patients receiving certain
treatments, such as multiple-day schedules with cisplatin or treat-
ment with some oral agents (including ceritinib or crizotinib) on a
daily continuous schedule, where long-term low-grade nausea or
vomiting may severely impact the patient’s quality of life.
2.3. CINV in breast cancer patients
Table 4 presents an overview of reported incidence rates of CINV
caused by multiple-day chemotherapy regimens commonly
administered for different types of breast cancer [76–81].
Table 1. (Continued).
Cancer site Epidemiology Antitumor treatment
Acute
lymphoblastic
leukemia
(ALL)
● The most common neoplasm in children; relatively rare in adults
● Incidence: bimodal age distribution; peaks at 2–5 years and over 50
years [54]
● More common in males (2:1 male:female) [55]
● Treatment is divided into phases: induction, consolidation,
maintenance, and prophylaxis of CNS involvement [56]. The
intensive therapeutic approach consists of active drugs with
different mechanisms of action and administered at their
maximum dose, to achieve a rapid reduction in the tumor mass
and avoid inducing resistance
● Induction: Combination treatment with multiple drugs (including
vincristine, prednisone, and anthracyclines), commonly administered
in combination with L-asparaginase or Peg-asparaginase and meth-
otrexate, the latter agent administered by intrathecal injection for
CNS prophylaxis [56]
● Consolidation: drugs such as cytarabine or high-dose methotrexate,
which have the advantage of being able to pass through the blood-
brain barrier for CNS prophylaxis [56]
● Maintenance: based on a combination of drugs such as 6-mercap-
topurine and methotrexate, with monthly re-induction using vin-
cristine and prednisone given for 2–3 years [56]
● For patients deemed at high risk, therapy is intensified through
bone marrow transplantation procedures [57,58]
● TKIs have improved the prognosis for patients with the Philadelphia
chromosome (a short chromosome 22 resulting from reciprocal
translocation between chromosomes 9 and 22) [59]
● CNS involvement (5–8% of patients): prophylaxis and treatment may
include intrathecal administration (via lumbar puncture) of metho-
trexate, alone or in combination with cytarabine and prednisone,
systemic treatment with high doses of cytarabine and/or metho-
trexate, and cranial irradiation [60]
CNS, central nervous system; EGFR, epidermal growth factor receptor; FOLFOXIRI, irinotecan, oxaliplatin, 5-fluorouracil, and leucovorin; HPV, human papillomavirus;
NSCLC, non-small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; RT, radiation therapy; SCLC, small cell lung
cancer; TKI, tyrosine kinase inhibitor; US, United States
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The oral version of cyclophosphamide, methotrexate and 5-
fluorouracil with a concomitant 14-day administration of
cyclophosphamide has shown moderate potential for causing
nausea/vomiting [82].
Numerous other regimens were associated with a low
emetogenic potential: oral hormonal therapy (tamoxifen, aro-
matase inhibitors, and megestrol) [83,84], targeted therapy
with lapatinib or everolimus [85,86], palbociclib or ribociclib
plus letrozole (as first-line therapy in metastatic hormone
receptor-positive patients) [87,88], and abemaciclib plus letro-
zole/anastrazole [89].
2.3.1. Unmet needs in the control of nausea and vomiting
in this patient population
CINV is still a critical issue in breast cancer patients. As outlined
herein, numerous chemotherapeutic agents are commonly used
for breast cancer, including new agents, and they have emeto-
genic potential, particularly when administered in combination
regimens. The high risk for emesis in this group may be due not
only to chemotherapy but also to patient-specific risk factors
(female, often aged <50 years old, and anxious about their diag-
nosis and disease prognosis). Although guidelines recommend a
triple antiemetic combination (consisting of a neurokinin 1 recep-
tor antagonist (NK1 RA), 5HT3 RA and dexamethasone ± olanza-
pine) in patients receiving an AC-based regimen, evidence-based
guidelines lack recommendations that address CINV related to
other antineoplastic schemes, highlighting the need for specific
antiemetic strategies to control this unpleasant symptom.
2.4. CINV in upper gastrointestinal tract cancer patients
2.4.1. Gastric cancer
In the ToGA trial, the incidences of nausea and vomiting were
similar in patients receiving trastuzumab plus chemotherapy
and those receiving chemotherapy alone (Table 5) [90],
demonstrating the minimal emetic potential of trastuzumab.
Vascular endothelial growth factor receptor 2 (VEGFR-2)
plays a role in gastric cancer pathogenesis and progression.
The RAINBOW study explored the role of ramucirumab, a
monoclonal antibody directed against VEGFR-2, with or with-
out paclitaxel. Overall survival was longer in the exploratory
arm than the control arm, and the regimen was associated
with a low rate of gastrointestinal toxicity, especially in terms
of CINV (grade 3 nausea: 2.0%; Table 5) [91].
In addition to CINV, patients with this disease may also
have an increased risk of nausea and vomiting due to the
risk of esophageal-gastric obstruction.
2.4.2. Pancreatic cancer
In a trial in patients with pancreatic cancer, the rates of vomiting
(grade 3–4) were 14.5% with FOLFOXIRI (irinotecan, oxaliplatin,
5-fluorouracil, and leucovorin) and 8.3% with gemcitabine [92].
In another trial, there was no grade 3–4 nausea and vomiting in
patients receiving nanoparticle albumin-bound (nab)-paclitaxel
in combination with gemcitabine; this result is unsurprising,
given the low emetogenic potential of these agents [93].
In patients with pancreatic cancer, disease-related factors
such as bowel obstruction and cachexia can influence the
incidence and severity of CINV.
2.4.3. Biliary tract cancer
In one trial, when patients were randomly assigned to receive
cisplatin (25 mg/m2) plus gemcitabine (1,000 mg/m2) on day 1
and 8 every 3 weeks or gemcitabine alone, rates of nausea and
vomiting were very low in both arms (about 4.0–5.0%) [94];
given that cisplatin is considered to be highly emetogenic,
regardless of dose, this result is surprising.
2.4.4. Unmet needs in the control of nausea and vomiting
in the upper gastrointestinal tract cancer population
Overall, the most common combination regimens used for
upper gastrointestinal malignancies are characterized by a
Table 2. Emetic symptoms associated with different cisplatin schedules in head and neck cancer [62]a.
Single-day regimen
(n = 190)b
Multiple-day regimen
(n = 45) b
Nausea
Incidence, % pts
Overall 73.7 48.9
Acute 33.6 42.2
Delayed 51.5 44.4
Trajectory
Study day with most pts experiencing nausea/% pts 3/65.5 5/42.2
Study day with most severe nausea experienced/% pts (severity)c 2/24.3 (moderate), 8.5 (severe) 7/22.2 (moderate), 4.4 (severe)
Vomiting
Incidence, % pts
Overall 24.7 28.9
Acute 12.3 20.0
Delayed 221.1 20.0
Trajectory
Study day with most pts experiencing vomiting/% pts 3/14.1 7/13.3
Study day with most severe vomiting experienced/% pts (severity)d 5/6.8 (grade 2),
1.7 (grade 3)
7/6.7 (grade 2), 4.4 (grade 3)
aProspective observational study in 235 adult patients with head and neck cancer receiving cisplatin-based chemotherapy; 75.7% of pts were male, 81.7%
were Chinese, and their mean age was 49.5 years.
bSingle-day regimen: cisplatin 40 mg/m2/day every 7 days or 100 mg/m2/day every 2 days; Multiple-day regimen: cisplatin 20 mg/m2/day for 4 days +
concurrent 5-FU 1 g/m2/day for 4 days.
cModerate nausea: 4–6 episodes, severe nausea: 7–10 episodes.
dGrade 2 vomiting: 2–5 episodes in 24 h, grade 3 vomiting: ≥6 episodes in 24 h.
5-FU, fluorouracil; pts, patients
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moderate gastrointestinal toxicity profile, especially when oxa-
liplatin is included instead of cisplatin [95].
However, patients suffering from upper gastrointestinal cancer
may be particularly susceptible to complications arising from
poorly controlled CINV, such as dehydration, nutrient depletion,
metabolic imbalances, and performance status deterioration, all of
whichmay impair their quality of life. These conditions sometimes
interfere with chemotherapy by causing dose reductions, delays,
or discontinuations [96]. Therefore, CINV can exacerbate concur-
rent symptoms caused by the disease itself, and is more likely to
develop when combination chemotherapy regimens are used.
2.5. CINV in colorectal cancer patients
According to the 2016 MASCC/ESMO guideline, the agents
used in the treatment of metastatic colorectal cancer (CRC)
are classified as moderate risk (irinotecan and oxaliplatin), low
risk (5-fluorouracil), and minimal risk (bevacizumab and cetux-
imab) for CINV causation [16]. The FOLFOXIRI regimen may be
more appropriately considered as moderate/high risk; how-
ever, being a combination chemotherapy regimen, the eme-
togenic potential of this combination is not specified in the
antiemetic guidelines.
The proportion of patients who experienced nausea and
vomiting while receiving multiple-day regimens in clinical stu-
dies are shown in Table 6 [97–105]. Other possible risk factors for
CINV in colorectal cancer patients are bowel obstruction or
electrolyte imbalances.
2.5.1. Unmet needs in the control of nausea and vomiting
in this patient population
International guidelines recommend using 5-HT3 RA (day 1) in
combination with dexamethasone (days 1–3) to prevent CINV
associated with chemotherapy with moderate emetic risk, with
the exception of carboplatin, for which guidelines recommend
using a 3-drug antiemetic regimen, including an NK1 RA [8,16].
The most recent guidelines from the NCCN recommend that
NK1 RAs should be given selectively to patients with additional
risk factors or to those who experienced CINV during previous
therapy while receiving two-drug antiemetic medication [9].
There is a paucity of evidence from the literature on the
management of delayed nausea and vomiting in patients
treated with oxaliplatin- or irinotecan-based chemotherapy
regimens.
In a prospective study, oxaliplatin-induced delayed nausea
in 10% of patients. The use of a 5-HT3 RA and dexamethasone
prior to oxaliplatin resulted in excellent control of nausea and
vomiting during the 24 h after chemotherapy (complete
response in 90% of patients). However, without further antie-
metic treatments, only 54% had a complete response during
the delayed phase [106]. Therefore, routine antiemetic prophy-
laxis for delayed nausea and vomiting following oxaliplatin-
based chemotherapy should be recommended. The use of
dexamethasone on days 2 to 3, granisetron transdermal
patch 24 h before chemotherapy or palonosetron on day 1
of therapy can be considered [16,107].
A 2011 study demonstrated that irinotecan has a modest
tendency to cause delayed nausea and vomiting. Without anyTa
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further antiemetic treatment, most patients (82%) do not
experience delayed emesis or require rescue antiemetics.
Routine prophylaxis for delayed emesis following irinotecan
does not appear to be warranted. As observed in other stu-
dies, patients not achieving a complete response during the
first 24 h after chemotherapy may have a higher risk of
delayed emesis [108]. Therefore, patients not achieving a com-
plete response during the first 24 h should receive prophylaxis
for delayed nausea and vomiting similar to that used for
patients treated with oxaliplatin-based regimes.
2.6. CINV in gynecological cancer patients
Many of these patients are treated with highly emetogenic
(cisplatin based) and moderately emetogenic (carboplatin
based) chemotherapy. Additionally, factors that can increase
their risk of emesis include that these patients are female, and
many of them have abdominal disease (e.g. ovarian or cervical
cancer) and are at increased risk for bowel obstruction. Pain
management medications such as opioid analgesics, which are
often required in these patients, can also worsen nausea and
vomiting.
In a post-hoc subset analysis of two trials, the fixed-combi-
nation antiemetic netupitant/palonosetron plus dexametha-
sone was effective at preventing CINV in patients with
gynecological cancers who were receiving cisplatin- or carbo-
platin-based chemotherapy; the proportion of patients experi-
encing no significant nausea was >90% in the acute phase and
>80% in the delayed phase [109].
2.7. CINV in soft-tissue sarcoma patients
In our clinical experience, the emetogenic potential of chemother-
apy for soft-tissue sarcoma (STS) varies depending on whether
they are used as single agents (e.g. moderate for anthracyclines,
ifosfamide, and trabectedin, low for paclitaxel and pazopanib) or
as combination regimens: high for ifosfamide + epirubicin, etopo-
side + ifosfamide, and doxorubicin + dacarbazine; moderate for
ifosfamide + epirubicin and gemcitabine + docetaxel. The addition
of olaratumab to doxorubicin or its use as maintenance mono-
therapy does not require a modification of the antiemetic prophy-
laxis, since olaratumab is characterized by a low emetogenic
potential [9].
According to the ASCO, MASCC/ESMO and NCCN guide-
lines, the recommended antiemetic prophylaxis for a highly
emetogenic chemotherapy includes the use of three drugs
(dexamethasone, single dose of 5-HT3 RA and NK1 RA) in the
acute phase and, in the late phase, of dexamethasone (from
day 2 to day 4) + aprepitant, depending on the NK1 RA used in
the acute phase [8,9,16].
Alternatively, in patients receiving moderate emetic risk che-
motherapy, the combination of 5-HT3 RA + dexamethasone is
used as CINV prophylaxis during the acute phase and dexametha-
sone alone is administered in the late phase (days 2 and 3) [8,9,16].
2.7.1. Unmet needs in the control of nausea and vomiting
in this patient population
Sometimes, STS patients are treated with alternating combina-
tion chemotherapies, resulting in the frequent occurrence of
intercycle nausea. The issue of how best to minimize intercycle
nausea is still a matter of debate, as is the optimal approach to
rescue therapy in order to maximize adherence to chemother-
apy. Furthermore, STS patients are often young adults; their
young age and possible high anxiety regarding prognosis and
treatment outcomes can increase their risk of CINV.
2.8. CINV in melanoma patients
Adjuvant therapy is historically based on interferon for which,
depending on the dosage, antiemetic prophylaxis can be
avoided [110]. Similarly, no specific prophylaxis is required in
patients receiving newer immunotherapy agents (ipilimumab,
pembrolizumab, nivolumab, and their combinations) [8,9,16].
Targeted treatments, such as BRAF inhibitor monotherapy
(dabrafenib, vemurafenib) are deemed to have a low or
minimal emetogenic potential and therefore require the adminis-
tration of a single antiemetic drug for acute phase prophylaxis
(dexamethasone, 5-HT3 RA, or metoclopramide) and no therapy in
Table 5. Incidence rates of nausea and vomiting induced by multiple-day chemotherapies commonly used for gastric cancer in clinical practice, as reported in the
scientific literature.
Study [reference] Multiple-day regimen Relevant patient characteristics
Incidence (% patients)
Nausea Vomiting
Bang et al. (2010) [90] 21 day cycles: Capecitabine (oral 1000
mg/m2 BID, days 1–14) OR fluorouracil
(IV infusion 800 mg/m2/day) +
cisplatin (IV infusion 80 mg/m2 on day 1)
+ trastuzumab IV infusion, 8 mg/kg on
day 1 of the first cycle,
then 6 mg/kg on day 1 of subsequent
cycles)
Patients with HER2-positive advanced
gastric or gastro-esophageal junction
cancer
67 (All grades)
7 (Grade 3–4)
50 (All grades)
6 (Grade 3–4)
21 day cycles: Capecitabine (oral 1000
mg/m2 BID, days 1–14) OR fluorouracil
(IV infusion 800 mg/m2/day) +
cisplatin (IV infusion 80 mg/m2 on day 1)
Patients with HER2-positive advanced
gastric or gastro-esophageal junction
cancer
63 (All grades)
7 (Grade 3–4)
46 (All grades)
8 (Grade 3–4)
Wilke et al. (2014) [91] 28-day cycles: Ramucirumab 8mg/kg (IV
days 1, 15), paclitaxel 80mg/kg (IV days
1, 8, 15)
Patients with previously- treated
advanced gastric or gastro-esophageal
junction adenocarcinoma
33 (Grade 1–2)
2 (Grade 3–4)
24 (Grade 1–2)
3 (Grade 3–4)
28-day cycles: Placebo (IV days 1, 15),
paclitaxel 80mg/kg (IV days 1, 8, 15)
30 (Grade 1–2)
2 (Grade 3–4)
17% (Grade 1–2)
4 (Grade 3–4)
BID, twice daily; HER2, human epidermal growth factor receptor 2; IV, intravenous.
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the delayed phase [8,9,16]. The mitogen-activated protein kinase
inhibitors cobimetinib and trametinib are not covered in the
current guidelines; however, as they also have low-to-minimal
emetogenic risk, the same anti-emetic approach may be used.
In light of recent innovations, the role of chemotherapy in
melanoma is more marginal and the drugs used, such as
dacarbazine (high emetic risk), fotemustine and temozolomide
(moderate) and taxanes (low), should be administered with
appropriate prophylaxis according to the emetogenic risk as
described in the existing guidelines [8,9,16].
2.8.1. Unmet needs in the control of nausea and vomiting
in this patient population
The impact of therapeutic innovation on the management of
CINV has been much lower in melanoma than in other can-
cers, given the limited emetic effect of the new drugs used.
2.9. CINV in myelodysplastic syndrome patients
Myelodysplastic syndrome (MDS) is a heterogeneous group of
hematologic diseases resulting from a clonal disorder of plur-
ipotent hematopoietic stem cells [111,112]. MDS is classified as
either primary (de novo) or secondary; in the latter, it is possi-
ble to identify a previous hemopathy or exposure to myelo-
toxic substances.
Drugs used in low-risk/intermediate-1 risk MDS and immu-
nomodulatory agents such as lenalidomide (Table 1) are not
emetogenic. Demethylating agents (Table 1) are characterized
by a moderate emetic risk. Nausea induced by these drugs
may be managed with a prophylactic regimen of oral antie-
metic agents (ondansetron/granisetron/metoclopramide)
before starting on the 7 days of subcutaneous chemotherapy
administration.
2.9.1. Unmet needs in the control of nausea and vomiting
in this patient population
Many patients with myelodysplasia are elderly and already
have concomitant conditions that negatively impact their
quality of life and require daily administration of multiple
medications. For these patients, offering antiemetic prophy-
laxis via an alternative route to oral therapy may be conveni-
ent and advantageous.
2.10. CINV in acute myeloid leukemia patients
The number of studies on nausea and vomiting in patients
with acute myeloid leukemia (AML) is limited (Table 7) [113]. It
has been observed that more than 70% of patients have no
nausea in the first 24 h of chemotherapy and about 50%
experience emesis in the following days [114]. Mattiuzzi and
colleagues compared the effect of ondansetron and palonose-
tron in patients treated with high doses of cytarabine, and
found no significant difference in the incidence of acute nau-
sea between the two treatment groups; however, patients
treated with palonosetron had significantly less delayed nau-
sea compared with the group receiving ondansetron [114].
According to recent guidelines, in patients receiving mod-
erately or highly emetogenic multiday chemotherapies (fludar-
abine in combination with cytosine arabinoside and idarubicin
at intermediate/high doses), it is advisable to use an NK1 RA in
conjunction with a 5-HT3 RA and dexamethasone [8,9,16].
However, prolonged use of dexamethasone should be
avoided because of the well-established side effects (insomnia,
agitation, etc.) and increased susceptibility to infections [115].
In older patients treated with demethylating agents, nau-
sea is managed with prophylactic antiemetic treatment using
ondansetron, granisetron, or metoclopramide administered
intravenously or orally before and during the course of
chemotherapy.
2.10.1. Unmet needs in the control of nausea and
vomiting in this patient population
Because of the advanced age of most AML patients, they
frequently have concomitant diseases requiring multiple oral
medications, which can negatively affect their quality of life.
For these patients, the availability of an alternative route to
oral therapy would therefore be useful.
Breakthrough emesis is still difficult to manage and is often
irreversible. In such cases, antiemetic administration via the
oral route is not feasible, so intravenous, transdermal, or rectal
administration is required.
2.11. CINV in acute lymphoblastic leukemia patients
In patients with acute lymphoblastic leukemia (ALL), the inten-
sive therapeutic approach consists of active drugs with differ-
ent mechanisms of action and administered at their maximum
dose, to achieve a rapid reduction in the tumor mass and
avoid inducing resistance.
There is limited information on nausea/vomiting in hema-
tologic diseases, particularly concerning CINV in ALL. Nausea is
managed with prophylactic antiemetics (ondansetron, grani-
setron, or metoclopramide) administered intravenously or
orally before and during chemotherapy [10,116,117].
The ondansetron and aprepitant combination appears to
be effective at preventing nausea and vomiting in patients
undergoing multiday moderately/highly emetogenic che-
motherapy [10,116,117].
Table 7. Response rates to antiemetic regimens in patients with hematologic malignancies (including acute myeloid leukemia) receiving multiple-day chemother-
apy, as reported in the scientific literature.
Study [reference] Patient characteristics
Number of
patients Antiemetic regimen
Absence of nausea and
vomiting
Musso et al. (2009)
[113]
Hematologic malignancy
- Non-Hodgkin lymphoma
- Hodgkin disease
- Acute myeloid leukemia
- Solid tumor
46 Palonosetron and dexamethasone before
chemotherapy
80%
Ondansetron and dexamethasone before
chemotherapy
60%
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3. RINV in different pathological conditions
3.1. RINV in patients with brain, head and neck, thorax
and upper trunk cancers
3.1.1. Overview
RINV is a common and troublesome side effect experienced by
patients undergoing RT. It is commonly believed to be an
exclusive or, at least, prevalent symptom of abdomen RT, but
a significant percentage of patients undergoing RT in other
parts of the body, like head and neck and thorax, also experi-
ence RINV. In this context, at the beginning of the 1990s,
Scarantino et al. suggested that serotonin could play a role
in mediating RINV induced by RT in the upper body: they
documented an increase in urinary levels of the serotonin
active metabolite 5-hyroxyindoleacetic acid following emeto-
genic upper and mid hemibody irradiation, and the efficacy of
5-HT3 RAs in the prevention of RINV [118,119].
3.1.2. Radiation therapy and incidence rates of RINV
According to the MASCC Consensus Conference on Antiemetic
Therapy, the emetogenic potential of radiation alone is classi-
fied as ‘low’ (30–60%) for RT of the brain, head and neck, and
thorax, and as ‘minimal’ for RT of the breast (<30%) [11,12].
However, these guidelines were prepared before the imple-
mentation of intensity-modulated radiation therapy (IMRT)
and have not been significantly updated since 2016 [16].
In the IGARR study, a prospective observational multicenter
trial of 1020 patients treated with RT (with or without che-
motherapy) at 45 Italian radiation oncology centers, nausea,
and vomiting were most common in patients treated for brain
cancer, followed by those treated for cancer of the thorax,
head and neck, and breast (Table 8) [19].
The pathophysiological mechanism of RINV in patients with
brain cancer or HNC is probably linked to a release of seroto-
nin from the chemoreceptor trigger zone in the brainstem (the
area postrema and dorsal vagal complex) when it is included
in the radiation portals [120–122]. In Rosenthal’s experience
[120], the incidence of nausea and vomiting is associated with
irradiation of the area postrema at a dose >36 Gy for patients
treated using IMRT [120]. This observation was confirmed by
Ciura et al. [122], who suggested that RINV developed around
the second week of treatment, with a possible correlation
between dose and toxicity in the range of 15 Gy to 25 Gy. In
both these experiences, the incidence of RINV in patients with
HNC was higher when IMRT was combined with emetogenic
chemotherapy compared with the incidence typically reported
for the same chemotherapy used in combination with 3D
conformational RT or compared with IMRT alone (Table 8).
Kocak-Uzel and colleagues [123] have also shown that, in
patients with HNC receiving definitive IMRT, the development
of RINV was related to the dose of radiation delivered to
specific CNS non-target structures, including the area post-
rema and dorsal vagal complex [123]. Practical contouring
guidelines of brainstem structures involved in the occurrence
of RINV (according to a magnetic resonance-based atlas) have
been recently published [124].
Unlike what we know about the causes of RINV in brain and
head and neck RT, the cause and mechanisms of RINV are still
unclear in patients undergoing chest RT when the upper abdo-
men is not included in the treatment volume. The irradiated
volume is one determinant of risk for RINV, in addition to irradia-
tion site, gender, previous or concurrent chemotherapy. IMRT
and volumetric modulated arc therapy (VMAT), which are
increasingly used for cancer treatment, can reduce acute toxicity
by decreasing the radiation doses to uninvolved healthy tissue
near the tumor targets; however, previously unaffected tissues,
such as the celiac plexus and gastroesophageal junction (GEJCP)
for breast or thorax cancers, may receive clinically significant
doses that lead to side effects such as nausea and vomiting [125].
After having observed unanticipated RINV in some breast
cancer patients treated with postoperative upper trunk IMRT-
VMAT, an Italian study group hypothesized that these symp-
toms could be attributed to an unduly dispensed dose to the
upper abdominal anatomical structures underlying the plan-
ning target volume [125]. In a retrospective analysis of stan-
dard weekly management visit forms, these researchers found
>60% of patients with breast cancer experienced acute RINV
(Table 8). Using the original planning computed tomography
(CT) scans, the researchers retrospectively contoured a volume
containing the anatomical structures relevant to the emesis-
related vagal parasympathetic afferent pathways, such as the
GEJCP. RINV was significantly related to a maximal dose >10
Gy and a mean dose <3 Gy to the GEJCP (P < 0.001). The
development of RINV was weakly correlated with irradiation of
the left breast (P < 0.01) and a planned treatment volume
>700 cm3 (P < 0.03), but no correlation was observed with age,
previous systemic therapy, or nodal irradiation [125].
Palliative hypofractionated radiotherapy (8 Gy/1 fraction or
20 Gy/5 fractions) of the spine has been classified as a mod-
erately emetogenic treatment schedule. Dexamethasone
monotherapy given on the day of irradiation is not sufficient
to control delayed nausea and vomiting; a prospective pilot
study suggested that the combination of aprepitant and gran-
isetron may provide more effective prophylaxis [126].
Table 8. Incidence rates of nausea and vomiting induced by radiation therapy in patients with brain, head and neck, thorax, and upper trunk cancers, as reported in
the scientific literature.
Study [reference] Regimen Relevant patient characteristics
Incidence (% patients)
Nausea Vomiting
IGARR study, Maranzano et al. (2010) [19] Radiotherapy or radiotherapy + chemotherapy Brain cancer 35.0 19.1
Thorax cancer 30.0 17.7
Head and neck cancer 28.4 11.9
Breast cancer 22.8 6.0
Rosenthal et al. (2008) [120] IMRT Head and neck cancer 76 38
IMRT + cisplatin-based chemotherapy Head and neck cancer 98 68
Lazzari et al. (2017) [125] Adjuvant VMAT Breast cancer 55 (all grade 1 or 2) 7 (all grade 1)
IGARR, Italian Group for Antiemetic Research in Radiotherapy; IMRT, intensity-modulated radiation therapy; VMAT, volumetric modulated arch therapy.
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3.1.3. Unmet needs in the control of nausea and vomiting
in this patient population
The literature on RINV related to the new radiation techniques,
such as IMRT and VMAT, is still not extensive. The VMAT modality
has become an increasingly implemented radiation technique for
cancer, but the paths of the arc beams often cross healthy struc-
tures that would not be directly irradiated if using 3D-conforma-
tional RT techniques. This effect is responsible for a new acute
morbidity profile not seen before the IMRT era [125]. Well-
designed prospective randomized trials are needed to investigate
(1) how modern radiotherapy modalities induce these symptoms,
(2) the maximum doses' targets can receive to avoid these side
effects, (3) suitable supportive therapy to prevent or minimize
discomfort in patients. Such studies will help to identify treatment
planning solutions that can be integrated into future IMRT VMAT
treatments.
3.2. RINV in gastrointestinal cancer patients
To date, the largest observational studies on RINV have been
conducted by the IGARR group and evaluated a total of 1,934
patients [19,20]. Within these studies, 29% of the patients who
received RT to the upper abdomen reported vomiting and
56% experienced nausea. In a smaller observational series,
63% of patients treated with abdominal or pelvic RT experi-
enced nausea [127]. In a prospective study including 45
patients with gastrointestinal cancers undergoing abdominal
and/or pelvic RT with curative or palliative intent, alone or
with concomitant chemoradiotherapy, nausea was reported in
83% of patients and emesis in 54% [128].
3.2.1. Unmet needs in the control of nausea and vomiting
in this patient population
The neurotransmitter serotonin is thought to be themost impor-
tant chemical mediator of RINV. The gastrointestinal tract houses
approximatively 95% of the body’s serotonin and is an important
anatomic region related to RINV [129]. According to antiemetic
practice guidelines, radiation treatments to the upper abdomen
are consideredmoderately emetogenic, with an estimated risk of
60–90% [12,16]. In patients receiving radiotherapy with moder-
ate emetogenic risk, antiemetic prophylaxis using a 5-HT3 RA is
recommended, with the option of combining this with a short
course (day 1–5) of dexamethasone [12,16].
As stated in the guidelines [12,16], although all chemother-
apy drugs associated with RT for the treatment of cancer of
this body region belong to the intermediate-low risk class, the
antiemetic prophylaxis strategy should take into account the
intermediate risk of RT itself [12,16].
Over the last two decades, the most extensively used antie-
metics for RINV in clinical practice have been the 5-HT3 RAs.
Many trials have reported that, in patients receiving upper
abdominal irradiation, 5-HT3 RAs provided significantly greater
protection against RINV than metoclopramide, phenothiazines,
or placebo [130,131].
The side effects of 5-HT3 RAs are generally mild and mainly
consist of headache, constipation, diarrhea, and weakness.
Furthermore, it has been suggested that these agents may
reduce the frequency of diarrhea, a debilitating adverse effect
of RT for acute gastrointestinal cancers [132].
The efficacy of antiemetic drugs in the treatment of RINV
has been studied in a few randomized clinical trials, and it
seems clear that the prevention of RINV must be preferred to a
rescue intervention [132].
However, the appropriate duration of antiemetic prophylaxis
for patients receiving fractionated RT has not been determined,
since there are no randomized trials comparing a five-day course
of 5-HT3 RA treatment with a more prolonged period [132].
Nonetheless, according to a systematic review including 25
randomized and non-randomized trials, 5-HT3 RAs appear to
be most commonly administered for the entire phase of radio-
therapy [132]. In short, the duration and the timing of therapy
with this class of antiemetics have not yet been defined and are
additional unmet needs in this field of research [132].
4. Suggestions for a practical approach to CINV and
RINV
The therapeutic armamentarium offers several options and
strategies to relieve CINV and RINV for particular cases and
conditions commonly observed in clinical practice, basing on
innovative drugs or on new formulations of known com-
pounds. For what concerns the latter case, we focused our
attention on transdermal granisetron as an example of pos-
sible advantages given by an ‘old’ drug given in a different
way, applied in different diseases. Based on the authors’
experience in managing CINV and RINV, several suggestions
are provided below.
We recommend that antiemetic therapy should be targeted
to the patient’s needs, based on the emetogenic potential of
their antineoplastic regimen, as defined by the antiemetic
guidelines, along with the characteristics of the disease and
the patient’s risk factors.
4.1. HNC treated concurrently with chemotherapy and RT
Patients with HNC often experience swallowing difficulties
related to tumor location and treatment consequences,
which may require a feeding tube in the last weeks of treat-
ment. In such circumstances, oral formulations of antiemetic
drugs are often difficult to administer, affecting compliance.
Using an alternative route of antiemetic administration could
overcome this problem, and deserves further clinical trials.
The transdermal formulation of the 5-HT3 RA granisetron
avoids the oral route of administration and could improve the
management of CINV in patients with HNC, by improving
compliance in patients with swallowing difficulties, allowing
them to receive optimal antiemetic dose intensity and protec-
tion from symptoms. This form of antiemetic therapy could
also benefit patients who are experiencing symptoms related
to RT (sticky saliva, mucositis, tube feeding, etc.) by providing
sustained protection against nausea and vomiting without the
need to swallow a tablet or capsule. Further studies are
needed to better position the use of transdermal granisetron
in the prevention and treatment of CINV in patients with HNC,
including evaluating its effects on quality of life.
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4.2. Upper gastrointestinal malignancies
For the most used RT regimens in these conditions, the use of 5-
HT3 RAs and dexamethasone seems to be adequate to control
RINV. For schedules with extended exposure to chemotherapy,
there may be potential for 5-HT3 RAs characterized by a pro-
longed action, such as the granisetron transdermal patch, to be
used. However, studies are needed to explore this potential.
4.3. STS
The granisetron transdermal patch may be considered appro-
priate in patients with sarcoma undergoing highly emetogenic
polychemotherapy administered over several days, particularly
in patients who have difficulty taking oral medications or have
a previous experience of nausea and vomiting not adequately
controlled by the prescribed antiemetic prophylaxis.
4.4. MDS
The transdermal formulation of granisetron may be an alter-
native route to oral therapy. It could be applied on the day
before demethylating therapy commences and kept in place
for up to 7 days.
This formulation does not require any special recommen-
dations and is extremely useful for elderly patients with swal-
lowing dysfunction, mucositis, gastropathy, and anorexia, and
may help to improve the quality of life of patients who are
already taking multiple oral medications.
4.5. Brain, head and neck, thorax and upper trunk
cancers treated with RT
In everyday practice, patients treated exclusively with RT on
the brain usually receive prophylactic dexamethasone.
RINV prophylaxis is not usually prescribed to patients irra-
diated for breast or chest neoplasms (lung, thymus, and upper
esophagus); these patients usually receive antiemetics only at
the onset of symptoms. When chemotherapy is associated
with radiotherapy, RINV prophylaxis should follow the guide-
lines provided for the most emetogenic treatment. In these
cases, the administration of transdermal granisetron is pre-
ferred in patients with swallowing difficulties.
4.6. Gastrointestinal cancer treated with RT
The AVERT study, a multicenter phase II trial, assessed the effec-
tiveness, safety, and tolerability of protracted dual NK1 RA and 5-
HT3 RA as RINV prophylaxis in patients receiving RT to the upper
abdomen and radiosensitizing chemotherapy. The authors con-
cluded that RINV still represents a serious morbidity in patients
receiving RT to the upper abdomen and that aprepitant plus
ondansetron, as dosed in this trial, were not superior to standard
ondansetron monotherapy. The authors noted that other poten-
tial prophylactic options may be considered for future investiga-
tions, such as the granisetron transdermal patch, intravenous
fosaprepitant, olanzapine, and alternative NK1 RA formulations
(e.g. the combination of netupitant and palonosetron and rola-
pitant as a single agent) [133].
4.7. Quadruple antiemetic combinations
Several studies have explored the potential benefit of combin-
ing four antiemetic agents to alleviate CINV in patients under-
going highly emetogenic chemotherapy (HEC; Table 9). In a
randomized, double-blind, phase III trial in 380 chemotherapy-
naïve patients with malignancies receiving HEC, the addition
of olanzapine significantly improved the antiemetic efficacy of
the three-drug regimen of a 5-HT3 RA, an NK1 RA and dex-
amethasone (Table 9) [134]. Based on the improvements
achieved with this new quadruple regimen, the ASCO and
NCCN antiemetic guidelines included this therapeutic option
in their recommendations [8,9].
In a single-blind, randomized trial in 97 chemotherapy-naïve
patients with breast cancer undergoing HEC, the addition of
metoclopramide to antiemetic prophylaxis with palonosetron,
aprepitant, and dexamethasone significantly improved the com-
plete response rate (Table 9) [135].
The efficacy of multi-drug combinations in managing CINV
probably arises from their ability to inhibit the emetic
response at multiple sites [136].
5. Conclusions
Many cancer patients are affected by CINV and RINV, and these
conditions are two of the major barriers to patient acceptance of
antineoplastic treatments. Nonetheless, continuous efforts and
Table 9. Efficacy of quadruple versus triple antiemetic therapy in patients receiving highly emetogenic chemotherapy.
Study [reference] Antiemetic therapy Relevant patient characteristics
Antiemetic efficacy (% patients)
No nausea in first
24 hours Complete response rate
Navari et al.
(2017) [134]
5-HT3 RA + NK1 RA +
dexamethasone +
olanzapine
Chemotherapy-naïve patients with malignancies receiving
cisplatin or cyclophosphamide + doxorubicin
chemotherapy (N = 380)
74 (P = 0.002)* Acute: 86 (P < 0.001)*
Delayed: 67 (P = 0.007)*
5-HT3 RA + NK1 RA +
dexamethasone +
placebo
45 Acute: 65
Delayed: 52
Oflazoglu et al.
(2018) [135]
Palonosetron + aprepitant +
dexamethasone +
metoclopramide
Chemotherapy-naïve patients with breast cancer
undergoing highly emetogenic chemotherapy (N = 97)
– 45.8 (P = 0.038)*
Palonosetron + aprepitant +
dexamethasone
– 26.5
*P-values vs triple antiemetic therapy.
5-HT3, serotonin; NK1, neurokinin 1; RA, receptor antagonist.
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scientific advances are being made to further develop novel ther-
apeutic options, formulations, and combination strategies of
antiemetic therapies. These will certainly contribute to extend
the availability of effective antiemetic treatments in the near
future, with the ultimate objective of providing promising solu-
tions tailored to suit the condition and the needs of each indivi-
dual patient.
6. Expert opinion
CINV and RINV are two of the most troublesome issues that
patients experience during anticancer treatment, with a high
impact on quality of life. Despite the great efforts and improve-
ments made in recent years, many areas of uncertainty and
unsolved issues still exist.
First of all, research should be tailored to identify more precise
treatment-, patient-, and disease-specific risk factors for the devel-
opment of nausea and vomiting. Until now, only limited clinical
predictive factors have been identified, but these have not yet
been included in the guidelines to differentiate preventive strate-
gies. In this regard, prospective studies aimed at personalizing
antiemetic therapies could be the next step in the landscape of
a tailored approach to supportive care in cancer. Moreover, the
impact of genomic predisposition to CINV and RINV should be
explored, by defining categories of risk and identifying possible
new targets for improving treatment of these symptoms.
Secondly, the cluster of symptoms linked to nausea and vomit-
ing should be better explored, in order to provide new information
about the associated patterns of toxicity. It is plausible that a better
control of CINV and RINV may positively impact other symptoms,
such as taste and swallowing, fatigue, anxiety, and depression. An
analysis of the patient-reported outcome (PRO) measures, listing
each symptom as perceived by the patients themselves, would
allow for a comprehensive assessment. Moreover, the analysis of
adverse events should not be limited to intensity or frequency, but
should also evaluate thedurationof symptomsof toxicity. For CINV
and RINV, one would assume that low-grade toxicities lasting
several days or weeks would deeply affect the quality of life of
patients, however this analysis is often lacking in many studies.
Thirdly, greater attention should be devoted to nausea and
vomiting with targeted agents, particularly when administered
orally for a long time. Some agents are associated with long-
lasting nausea, which bothers patients. The impact of nausea
with targeted therapy should be studied more broadly; in fact,
while there are data on the greater impact of nausea on
patient quality of life compared with the impact of vomiting,
this information is lacking for targeted agents [137]. Greater
efforts are needed to understand how to prevent and treat
nausea in such cases, as these treatments are often used for
periods lasting months or years.
Finally, the studies of new drug compounds or combinations
should proceed in parallel with the evaluation of different
schedules (intensified or de-intensified) of antiemetics and of alter-
native ways of drug administration. Moreover, the study of non-
pharmacological therapies should be encouraged, with the aim of
reducing CINV/RINV symptoms. Non-pharmacological approaches
equally deserve to be studied in a rigorous manner, using well-
designed trials, to precisely define the role of such strategies in
controlling nausea and vomiting.
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